Navigation Links
ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist

WASHINGTON, April 29, 2010 The American Chemical Society Green Chemistry Institute (ACS GCI) Pharmaceutical Roundtable has awarded its 2010 research grant to Scottish chemist David Cole-Hamilton, Ph.D., for making great strides in expanding green chemistry and engineering practices in the global pharmaceutical industry. Cole-Hamilton will use the one-year $150,000-grant to further his study of the hydrogenation of amides to amines, resulting in improved benefits for the environment. He is the Irvine Professor of Chemistry, EaStCHEM, University of St. Andrews, Scotland.

Cole-Hamilton's research seeks to provide safer and environmentally friendly solutions to convert amides to amines, important in the development of many pharmaceutically active compounds. Conversion of the amide to the amine is usually conducted using a metallic hydride source such as sodium borohydride or lithium aluminum hydride.

The reactions are stoichiometric and large amounts of aluminum- or boron- containing side products are formed. Requiring separation from the desired amine product, these side products are usually disposed of in a landfill. The Roundtable identified greener amide reductions as one of the 12 key green chemistry research areas important for the pharmaceutical industry.

Cole-Hamilton's study will build upon exciting preliminary results, which proved it should be possible to use catalytic amide hydrogenation, which would only give water as a side product. If the catalyst is very active or can be recycled, there is no need for any significant waste from this reaction.

Since 2007 the grant program has awarded $800,000 toward research in the 12 key green chemistry research areas. All funding is made possible by a partnership between the ACS GCI and an alliance of major pharmaceutical companies Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Codexis, Dr. Reddy's, DSM Pharmaceutical Products, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, and Roche.

Under the leadership of Cole-Hamilton, the St. Andrews group will collaborate with members of the Roundtable to improve the technology and allow it to be introduced widely and without restriction into the pharmaceutical industry. Major targets will be lowering the temperature and especially the pressure at which reactions are carried out, improving the selectivity toward the desired amines (currently 85-90 percent, with alcohols as the side products) and exploring scope and the functional group tolerance of the reaction.


Contact: Julie Manley
American Chemical Society

Related biology news :

1. Study gives green light to plants’ role in global warming
2. Georgia Powers Green Energy Program Redesigned to Include More Solar Power
3. New York City Regional Extension Center Selects Greenway
4. New evidence that green tea may help fight glaucoma and other eye diseases
5. From bacteria to electricity: The future of green energy
6. Demystifying yield fluctuations for greenhouse tomatoes
7. Solid-state illuminator reduces nitrates in leafy green vegetables
8. Global study shows health joins green as business strategy
9. Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet
10. Spray application rate, equipment affect pest management in greenhouse ivy plants
11. More maize ethanol may boost greenhouse gas emissions
Post Your Comments:
Related Image:
ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
Breaking Biology Technology: